“…During 2005–2015 the overall rate of PCS in FVG (19.6%) was substantially lower than the corresponding figure reported in 2010 for the entire Italy (29%) and still slightly under the most recent national PCS rate for 2017 (22.2%). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In this study, we aimed to figure out the relationship between DGP and autophagy of ICCs. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Interestingly, these distinct ALL samples (outlined in black on figures) showed relatively larger elastic moduli, higher AVG DoLP, and lower STD AoP (i.e., uniform and organized collagen alignment) across the stress-strain curve compared to samples harvested from knees without a distinct ALL. …”
Enlace del recurso
Enlace del recurso

“…LIMITATIONS, REASONS FOR CAUTION: Some data from the initial ESHRE certification programme were not obtained electronically, in particular data for education, implying tables and figures reflect the specified valid data periods. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…CONCLUSIONS: Overall, nearly 1 in 3 individuals have experienced negative effects on mental health during COVID-19, a figure that exceeds rates reported in front-line healthcare workers. …”
Enlace del recurso
Enlace del recurso

“…A smaller proportion of people had a plan for top-tier contraception among the COVID cohort compared with the pre-COVID cohort at both admission and discharge (46.0% vs 71.0%, P<.01 and 31.0% vs 37.9%, P=.05) (Figure). More than 80% of the people attended a routine postpartum visit in both cohorts (P=.30) with 17.7% being telehealth visits in the COVID cohort compared with telehealth not being offered pre-COVID. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This information also brings into question the appropriateness of holding the perceived dominant limb to higher standards or accepting lower standards for the non-dominant limb. TABLES AND FIGURES: REFERENCES: 1. Goekeler A, Welling W, Benjaminse A. …”
Enlace del recurso
Enlace del recurso

“…The mean of differences between preoperative and 24-month postoperative follow-up PROMs was 22.5 for mHHS, 17.4 for HOS-ADL, 32.7 for HOS-Sport, 22.9 for NAHS, 33.9 for iHOT-33. (Figure 1) The mean of differences between preoperative and final post-operative follow-up PROMs was 22.1 for mHHS, 17.6 for HOS-ADL, 33.2 for HOS-Sport, 23.3 for NAHS, and 34.2 for iHOT-33. …”
Enlace del recurso
Enlace del recurso

“…We advocate for the development and dissemination of evidence-based guidelines to manage SCD patients with COVID-19 to reduce morbidity and mortality in this at-risk population. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…Further examination of the mechanistic link between ABO antigens, antibodies and SARS-CoV-2, and its implications on controlling the current pandemic is warranted. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…By designing a donor protocol to obtain the ideal amount of CCP units, we were able to meet demand across a hospital system and treat patients at community hospitals in the network who may not have otherwise had access to this resource. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…Healthcare systems should use such data to emerge from the COVID-19 pandemic and retain the positive impacts such as telemedicine, while developing education materials and other resources to address the reported negative impacts where possible. [Figure: see text] DISCLOSURES: Mesa:CTI BioPharma: Research Funding; Promedior: Research Funding; Novartis: Consultancy; Sierra Oncology: Consultancy; Samus Therapeutics: Research Funding; Genentech: Research Funding; AbbVie: Research Funding; Incyte: Research Funding; LaJolla Pharmaceutical Company: Consultancy; Bristol Myers Squibb: Research Funding.…”
Enlace del recurso
Enlace del recurso

“…Furthermore, the reduction in chair time and patient convenience was largely beneficial in light of COVID-19 to minimize patient exposure in clinic. [Figure: see text] DISCLOSURES: Hughes:Rigel: Other: advisory board; Abbvie: Speakers Bureau; Amgen: Speakers Bureau; Karyopharm: Speakers Bureau. …”
Enlace del recurso
Enlace del recurso

“…Technological problems still represent a barrier to a wider application of telehealth monitoring systems in the medical setting. [Figure: see text] DISCLOSURES: Mussetti:Novartis, Gilead: Honoraria, Research Funding. …”
Enlace del recurso
Enlace del recurso

“…In addition, treatment pathways need to be instituted to not only treat COVID-19 infection, but also provide the best treatment for these patient's underlying HM. [Figure: see text] DISCLOSURES: Safah:Amgen: Honoraria; Verastem: Honoraria; Janssen: Speakers Bureau; Astellas: Speakers Bureau. …”
Enlace del recurso
Enlace del recurso

“…Further studies are needed to determine whether the possible interaction between edoxaban and the antiviral treatment used empirically for COVID-19 is clinically relevant. [Figure: see text] DISCLOSURES: Olivera:Boehringer Ingelheim: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; BAYER: Consultancy; Daiichi Sankyo: Consultancy, Speakers Bureau. …”
Enlace del recurso
Enlace del recurso

“…A larger prospective study across multiple regions of the United States should be considered to further assess the prevalence of SARS-CoV-2 in the African American community and the apparent increased rate of hospitalizations for SARS-CoV-2 infection in individuals with SCT. [Figure: see text] DISCLOSURES: Neuberg:Madrigak Pharmaceuticals: Current equity holder in publicly-traded company; Celgene: Research Funding; Pharmacyclics: Research Funding. …”
Enlace del recurso
Enlace del recurso

“…Caucasians were more likely to die from COVID-19 infection. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…Therefore, prospective studies are needed to analyze the impact of HIT on morbidity, mortality and long-term outcomes in COVID-19 patients. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…This signature may assist in identifying pts necessitating risk-adaptive interventions such as steroids, biologic agents and/or novel anti-inflammatory strategies. [Figure: see text] DISCLOSURES: Rivero:Incyte: Membership on an entity's Board of Directors or advisory committees; celgene: Membership on an entity's Board of Directors or advisory committees; agios: Membership on an entity's Board of Directors or advisory committees.…”
Enlace del recurso
Enlace del recurso